News | Patient Positioning Radiation Therapy | August 15, 2019

Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Maastro Proton Therapy center will deploy C-RAD Catalyst PT patient positioning system with Mevion S250i proton therapy system

Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

August 15, 2019 — Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton therapy system. The union of both products supports a seamless workflow with uninterrupted patient surface tracking and monitoring from setup through treatment.

C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy - the Catalyst PT, based on the Catalyst technology and software.

Maastro Proton Therapy (Maastricht, The Netherlands), equipped with the Mevion 250i Proton Therapy System, and C-RAD announced a strategic agreement in 2018 to install the Catalyst PT at the center. C-RAD and Mevion co-developed a solution based on both companies’ products that allows a high level of integration to enhance user comfort and patient safety.

Guided by the expertise and requirements of Maastro Proton Therapy, the two industry partners focused on developing the interface required to support a seamless workflow, including automatic patient position correction and monitoring throughout the entire treatment process.

The installation of the Catalyst PT at Maastro Proton Therapy was commissioned over the past month and has been released for clinical operation beginning this August. The center will be deploying the Catalyst PT especially for thoracic tumor indications treated on the Mevion system.

Geert Bosmans, managing director of Maastro Proton Therapy said, “To provide our patients with an improved high-quality treatment plan we installed the C-RAD surface tracking system in our center. We will use it to accurately position and continuously monitor our patients during treatment for increased high-precision radiation therapy.”

The Catalyst PT system is now available to current and future Mevion customers.

For more information: www.mevion.com, www.c-rad.com

Related Content

Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa
Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Attendees of ASTRO 2019 walked the halls of McCormick Place in Chicago, Ill.

Feature | ASTRO | October 30, 2019 | By Greg Freiherr
At the American Society for Radiation Oncology’s (ASTRO) 2019 a
Advanced Radiation Therapy Upgrades AccuBoost Digital Brachytherapy Platform
News | Brachytherapy Systems, Women's Healthcare | October 23, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, Sept. 15-18 in Chicago, Advanced Radiation...
MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment
News | Treatment Planning | October 18, 2019
The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an...
Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Low four-year rates of gastrointestinal (13.6 percent) and urologic issues (7.6 percent) suggest hypofractionated proton therapy as an alternative to traditional radiotherapy to reduce toxicity.

Feature | Prostate Cancer | October 16, 2019 | By Jeff Zagoudis
Radiation therapy is an important tool in the clinician’s armamentarium for treatment of localized, early-stage prost